ReviewJournal of human hypertension2006
Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes.
Review in Journal of human hypertension, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 61 citations in OpenAlex.
- Trial
- Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.Clinical journal of the American Society of Nephrology : CJASN · 2013Trial
- One-year renal and cardiac effects of bisoprolol versus losartan in recently diagnosed hypertensive patients: a randomized, double-blind study.Clinical drug investigation · 2009Trial
- Oxidative Stress in Kidney Injury and Hypertension.Antioxidants (Basel, Switzerland) · 2024Review
- Observational
- Development of a Longitudinal Diagnosis and Prognosis in Patients with Chronic Kidney Disease: Intelligent Clinical Decision-Making Scheme.International journal of environmental research and public health · 2021Article
- L-NAME Administration Enhances Diabetic Kidney Disease Development in an STZ/NAD Rat Model.International journal of molecular sciences · 2021Article
- Medications Activating Tubular Fatty Acid Oxidation Enhance the Protective Effects of Roux-en-Y Gastric Bypass Surgery in a Rat Model of Early Diabetic Kidney Disease.Frontiers in endocrinology · 2021Article
- Effect of fosinopril on the renal cortex protein expression profile of Otsuka Long-Evans Tokushima Fatty rats.Experimental and therapeutic medicine · 2020Article
- Effects of Chronic Administration of Capsaicin on Biomarkers of Kidney Injury in Male Wistar Rats with Experimental Diabetes.Molecules (Basel, Switzerland) · 2018Article
- Effects and mechanism of irbesartan on tubulointerstitial fibrosis in 5/6 nephrectomized rats.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2010Article
- Direct renin inhibitors: ONTARGET for success?International urology and nephrology · 2009Review
- New insights into the importance of aminopeptidase A in hypertension.Heart failure reviews · 2008Review
- Inhibition of the renin-angiotensin system and chronic kidney disease.International urology and nephrology · 2008Review
- Review
- The ADVANCE trial: further PROGRESS with HOPE.Journal of human hypertension · 2007Article
- Emerging insights in the first-step use of antihypertensive combination therapy.Journal of clinical hypertension (Greenwich, Conn.) · 2007Review
- The 2007 revised ESC/ESH Guidelines in the management of hypertension: clarifying individual patient care.Journal of human hypertension · 2007Article
- Combination therapy with an angiotensin-converting enzyme inhibitor and a calcium channel blocker.Journal of clinical hypertension (Greenwich, Conn.) · 2007Review
- Renin inhibition: the holy grail of renin-angiotensin system blockade?Journal of human hypertension · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of end-stage renal disease (ESRD) is rising worldwide, accompanied by corresponding increases in the risk of morbidity and mortality. Underlying this trend are increasing rates of hypertension and diabetes mellitus, the two most common causes of ESRD. In addition to the adverse haemodynamic effects of hypertension on the kidney, elevated blood pressure (BP) can activate components of the renin-angiotensin-aldosterone system (RAAS), which, in turn, activate mediators of inflammation, oxidative stress, cell growth, and matrix accumulation. Lowering BP reduces the risk of cardiovascular events and renal damage. Accumulating evidence from clinical and laboratory studies suggests that interrupting the RAAS with therapies such as angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone receptor blockers can interfere with the mechanisms that promote diabetic and non-diabetic renal damage. Moreover, clinical trials of RAAS blockade have demonstrated reductions in microalbuminuria, a predictor of increased cardiorenal risk and overt nephropathy in patients with and without diabetes and/or hypertension. In this way, agents that block the RAAS should be considered the drugs of first choice as they provide enhanced renoprotection compared with other classes of antihypertensive agents such as calcium channel blockers and beta-blockers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.